Please find attached Audited Financail Results for the quarter and year ended March 31, 2026
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma reported standalone PAT of ₹713.61 Crores for FY26, up 203% from ₹235.16 Crores in FY25. Full year standalone revenue grew 9.6% to ₹10,421.18 Crores. Q4 standalone revenue was ₹2,581.82 Crores with strong EBITDA margin expansion to 35% from 26% in Q3. The Board approved an additional investment of up to ₹500 Crores in wholly-owned subsidiary Mankind Medicare Private Limited, realigned NCD security cover post ₹1,250 Crores redemption, and reappointed Whole-Time Director Satish Kumar Sharma for another 5-year term. Key executive directors voluntarily waived their commission for FY25-26 to strengthen cash position for business expansion. Statutory auditors issued an unmodified opinion but included an Emphasis of Matter regarding ongoing income tax proceedings. Prior year figures were restated for the BSV acquisition.
Strong profitability growth and margin expansion are positive signals for shareholders. The tax proceedings remain a contingent liability, while the capital deployment in subsidiaries and executive commission waiver suggest management focus on long-term expansion over short-term payouts.